(E907) Lyxor 1 MDAX (DR) I - Ratings and Ratios
German Stocks, Small Cap, Equity
Description: E907 Lyxor 1 MDAX (DR) I
The Lyxor 1 MDAX (DR) UCITS ETF I (XETRA:E907) is a small-cap equity ETF designed to track the performance of small-cap companies in Germany. It replicates the MSCI Germany Small Cap NR EUR index, offering investors exposure to a diversified portfolio of German small-cap stocks. The ETF is listed on XETRA and is structured as a UCITS-compliant fund, ensuring transparency and regulatory compliance. It is tailored for investors seeking targeted exposure to the German small-cap market, which may include companies across various sectors such as technology, industrials, and consumer goods.
From a technical perspective, the ETF currently trades at 137.68 EUR, with a 20-day average volume of 2,182 shares. Its short-term trend indicators show the price slightly above the 20-day SMA (137.21) and 50-day SMA (131.97), while it remains below the 200-day SMA (129.38). The ATR of 1.71 indicates moderate price volatility over the past 20 days. These metrics suggest the ETF is in a consolidative phase, with potential resistance at the 200-day SMA level.
Fundamentally, the ETF manages an AUM of 132.51M EUR, reflecting its role as a niche small-cap fund. Its focus on small-cap German equities makes it sensitive to domestic economic conditions, including consumer spending, industrial production, and monetary policy. Investors should consider the ETFs liquidity profile, as small-cap stocks can experience higher volatility and lower trading volumes compared to large-cap counterparts.
Over the next three months, based on
Additional Sources for E907 ETF
E907 ETF Overview
Market Cap in USD | 155m |
Category | Germany Small/Mid-Cap Equity |
TER | 0.30% |
IPO / Inception | 2015-10-30 |
E907 ETF Ratings
Growth Rating | 3.45 |
Fundamental | - |
Dividend Rating | 56.7 |
Rel. Strength | -10.4 |
Analysts | - |
Fair Price Momentum | 146.47 EUR |
Fair Price DCF | - |
E907 Dividends
Dividend Yield 12m | 1.72% |
Yield on Cost 5y | 1.77% |
Annual Growth 5y | 13.05% |
Payout Consistency | 90.3% |
Payout Ratio | % |
E907 Growth Ratios
Growth Correlation 3m | 65% |
Growth Correlation 12m | 81.5% |
Growth Correlation 5y | -53% |
CAGR 5y | 1.78% |
CAGR/Max DD 5y | 0.04 |
Sharpe Ratio 12m | 1.73 |
Alpha | 6.21 |
Beta | 0.659 |
Volatility | 14.53% |
Current Volume | 0.2k |
Average Volume 20d | 0.4k |
Stop Loss | 143.9 (-3%) |
As of July 15, 2025, the stock is trading at EUR 148.40 with a total of 183 shares traded.
Over the past week, the price has changed by +0.91%, over one month by +2.42%, over three months by +14.26% and over the past year by +15.83%.
Neither. Based on ValueRay´s Analyses, Lyxor 1 MDAX (DR) I is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 3.45 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of E907 is around 146.47 EUR . This means that E907 is currently overvalued and has a potential downside of -1.3%.
Lyxor 1 MDAX (DR) I has no consensus analysts rating.
According to our own proprietary Forecast Model, E907 Lyxor 1 MDAX (DR) I will be worth about 165.2 in July 2026. The stock is currently trading at 148.40. This means that the stock has a potential upside of +11.31%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 165.2 | 11.3% |